Skip to main content
GRI
NASDAQ Life Sciences

GRI Bio Reports Positive Phase 2a Data for IPF Drug, Confirms Nasdaq Equity Compliance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.346
Mkt Cap
$3.016M
52W Low
$0.218
52W High
$15.47
52W Position info
59% above low
Off High info
98% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

GRI sits 59% above its 52-week low of $0.218.

Summary

GRI Bio announced additional positive Phase 2a clinical trial data for GRI-0621 in idiopathic pulmonary fibrosis, reinforcing its disease-modifying mechanism and earlier positive findings, while also confirming compliance with Nasdaq's minimum stockholders' equity requirement.


Key Events · Product Development and Regulatory · GRI

  • Positive Phase 2a Clinical Data

    GRI Bio announced additional positive flow cytometry data from the Phase 2a trial of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF), showing iNKT inhibition and an anti-fibrotic immunomodulatory shift.

  • Strengthened Proof-of-Concept

    The new data reinforces earlier findings on collagen turnover, lung tissue repair, and improved pulmonary function, strengthening the overall clinical proof-of-concept for GRI-0621.

  • Nasdaq Equity Compliance

    The company believes its stockholders' equity now exceeds the minimum $2.5 million Nasdaq requirement, following a public offering completed in December 2025.


Analysis · GRI · Life Sciences

This 8-K filing contains two significant positive updates for GRI Bio. The additional positive data from the Phase 2a clinical trial for GRI-0621 in idiopathic pulmonary fibrosis (IPF) strengthens the clinical proof-of-concept, demonstrating a clear immunomodulatory shift and consistency with earlier findings of fibrosis resolution and improved lung function. This de-risks the lead candidate and is a crucial step for a clinical-stage biotech. Concurrently, the company confirmed that its stockholders' equity now exceeds the Nasdaq minimum requirement following a recent public offering, removing a potential delisting overhang and improving investor confidence.

At the time of this filing, GRI was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.22 to $15.47. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRI - Latest Insights

GRI
Jun 18, 2026, 4:50 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.90
Real-time Price: $1.38 info
Change: -$0.5245 (-28%) info
Market Cap: $2.532M info
GRI
Jun 18, 2026, 8:31 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.23
Real-time Price: $1.38 info
Change: -$0.855 (-38%) info
Market Cap: $2.532M info
GRI
May 14, 2026, 8:36 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.30
Real-time Price: $1.38 info
Change: -$0.9294 (-40%) info
Market Cap: $2.532M info
GRI
May 13, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.26
Real-time Price: $1.38 info
Change: -$0.885 (-39%) info
Market Cap: $2.532M info
GRI
May 13, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.26
Real-time Price: $1.38 info
Change: -$0.885 (-39%) info
Market Cap: $2.532M info